Evidence map›Paper›PMID 31815127›Full record

ArticleBioMed research international2019

D-Ring-Modified Analogues of Luotonin A with Reduced Planarity: Design, Synthesis, and Evaluation of Their Topoisomerase Inhibition-Associated Cytotoxicity.

Abdulrahman I Almansour, Raju Suresh Kumar, Natarajan Arumugam, Giulia Bianchini, J Carlos Menéndez, Faruq Mohammad, Kotresha Dupadahalli, Mohammad Altaf

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Recent Advances in the Research on Luotonins A, B, and E.Molecules (Basel, Switzerland) · 2024
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Abdulrahman I AlmansourDepartment of Chemistry, College of Science, King Saud University, P. O. Box 2455, Riyadh 11451, Saudi Arabia.
Raju Suresh KumarDepartment of Chemistry, College of Science, King Saud University, P. O. Box 2455, Riyadh 11451, Saudi Arabia.ORCID https://orcid.org/0000-0003-3754-4223
Natarajan ArumugamDepartment of Chemistry, College of Science, King Saud University, P. O. Box 2455, Riyadh 11451, Saudi Arabia.
Giulia BianchiniUnidad de Química Orgánica y Farmacéutica, Departamento de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain.
J Carlos MenéndezUnidad de Química Orgánica y Farmacéutica, Departamento de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain.
Faruq MohammadSurfactants Research Chair, Department of Chemistry, College of Science, King Saud University, P. O. Box 2455, Riyadh 11451, Saudi Arabia.ORCID https://orcid.org/0000-0002-9318-9986
Kotresha DupadahalliDepartment of Botany, Davangere University, Shivagangothri, Davangere 577007, Karnataka, India.
Mohammad AltafDepartment of Chemistry, College of Science, King Saud University, P. O. Box 2455, Riyadh 11451, Saudi Arabia.
King Saud University · SAUniversidad Complutense de Madrid · ESDavangere University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A- and D-ring-modified luotonin-inspired heterocycles have been synthesized and were evaluated for their activity against the viability of four cancer cell lines in vitro, namely, MCF7, HCT116, JURKAT, and NCI-H460. The analysis of results indicated that two of the synthesized derivatives displayed good inhibition against the growth of the human colon cancer HCT116 cell line, with potencies lower than but in the same order of magnitude as camptothecin (CPT). These two luotonin analogues also showed an activity similar to that of the highly potent alkaloid CPT as inhibitors of topoisomerase I and also inhibited topoisomerase II. These results show that complete planarity is not a strict requirement for topoisomerase inhibition by luotonin-related compounds, paving the way to the design of analogues with improved solubility.

Indexed as

AlkaloidsAntineoplastic AgentsCamptothecinCell Line, TumorDNA Topoisomerases, Type IDNA Topoisomerases, Type IIEnzyme InhibitorsHumansMolecular Docking SimulationPoly-ADP-Ribose Binding ProteinsPyrrolesQuinonesSolubilityStructure-Activity RelationshipTopoisomerase InhibitorsAlkaloidsAntineoplastic AgentsCamptothecinDNA Topoisomerases, Type IDNA Topoisomerases, Type IIEnzyme Inhibitorsluotonin APoly-ADP-Ribose Binding ProteinsPyrrolesQuinonesTOP1 protein, humanTOP2A protein, humanTopoisomerase Inhibitors

Identifiers

PMID31815127
PMCPMC6877907
OpenAlexW2984821361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.